Durect announces fda advisory committee meeting to review posimir® for the treatment of post-surgical pain

Durect corporation announced that the u.s. food and drug administration (fda) has notified the company that its class 2 nda resubmission for posimir® (bupivacaine extended-release solution) will be discussed at a meeting of the anesthetic and analgesic drug products advisory committee (aadpac). the meeting is tentatively scheduled for january 16, 2020. the fda had previously assigned a user fee goal date of december 27, 2019; a new user fee goal date has not been assigned.
DRRX Ratings Summary
DRRX Quant Ranking